Clinical and prognostic features of E-cadherin in adenocarcinoma of the esophagogastric junction patients.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
10
12
2022
medline:
3
2
2023
entrez:
9
12
2022
Statut:
ppublish
Résumé
The expression, activity, and functional role of E-cadherin in adenocarcinoma of the esophagogastric junction (AEG) are unclear. In this research, we evaluated the expression of E-cadherin in AEG, as well as its clinicopathological significance and prognostic value. A total of 65 AEG samples and 10 normal paracancerous tissues undergoing AEG resection in thoracic surgery were collected. The samples were immunohistochemically examined for expression levels of E-cadherin. The Chi-square test was used to determine if E-cadherin expression correlated with the clinicopathological features of AEG patients. The link between clinicopathological features and 5-year survival rates was investigated using Kaplan-Meier survival curves and multifactorial Cox regression analysis. In AEG tissues, E-cadherin expression was considerably reduced. Differentiation grade ( P = 0.013), infiltration depth ( P = 0.033), and clinicopathological stage ( P = 0.045) were substantially linked to the level of E-cadherin expression. Five-year survival rates of AEG patients were affected by E-cadherin expression ( P = 0.037), tumor differentiation ( P = 0.010), lymph node metastasis ( P < 0.001), and clinicopathological stage ( P = 0.037). Tumor differentiation ( P = 0.033) and lymph node metastasis ( P = 0.001) were independent risk factors for shorter overall survival. E-cadherin expression in AEG was significantly decreased, which was strongly related to tumor differentiation, infiltration, and clinicopathological stage. An E-cadherin deficiency would lead to poor prognosis in AEG patients. E-cadherin may play a crucial role in AEG invasion and metastasis. Low expression of E-cadherin may be a potential early biomarker and overall survival predictor for AEG patients.
Identifiants
pubmed: 36484275
doi: 10.1097/CEJ.0000000000000776
pii: 00008469-202303000-00004
doi:
Substances chimiques
Cadherins
0
CDH1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-125Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Berk V, Deniz K, Bozkurt O, Ozaslan E, Karaca H, Inanc M, et al. (2015). Predictive significance of VEGF and HIF-1α expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab. Asian Pac J Cancer Prev 16:6149–6154.
Buda A, Pignatelli M (2011). E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. Cell Commun Adhes 18:133–143.
Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, et al. (2012). E-cadherin dysfunction in gastric cancer–cellular consequences, clinical applications and open questions. FEBS Lett 586:2981–2989.
Chevallay M, Bollschweiler E, Chandramohan SM, Schmidt T, Koch O, Demanzoni G, et al. (2018). Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Ann N Y Acad Sci 1434:132–138.
Clemons NJ, Phillips WA, Lord RV (2013). Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther 14:782–795.
Clevers H, Nusse R (2012). Wnt/β-catenin signaling and disease. Cell 149:1192–1205.
Corso G, Figueiredo J, De Angelis SP, Corso F, Girardi A, Pereira J, et al. (2020). E-cadherin deregulation in breast cancer. J Cell Mol Med 24:5930–5936.
de Manzoni G, Pedrazzani C, Pasini F, Durante E, Gabbani M, Grandinetti A, et al. (2003). Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol 29:506–510.
Dong H, Xie L, Tang C, Chen S, Liu Q, Zhang Q, et al. (2014). Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. Clin Transl Oncol 16:783–791.
Grabowska MM, Day ML (2012). Soluble E-cadherin: more than a symptom of disease. Front Biosci (Landmark edition) 17:1948–1964.
Hartsock A, Nelson WJ (2008). Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 1778:660–669.
He Y, Li D, Shan B, Liang D, Shi J, Chen W, et al. (2019). Incidence and mortality of esophagus cancer in China, 2008–2012. Chin J Cancer Res 31:426–434.
Hsu S-H, Chou L-F, Hong C-H, Chang M-Y, Tsai C-Y, Tian Y-C, et al. (2021). Crosstalk between E-Cadherin/β-Catenin and NF-κB signaling pathways: the regulation of host-pathogen interaction during leptospirosis. Int J Mol Sci 22: 13132.
Huang P, Yan R, Zhang X, Wang L, Ke X, Qu Y (2019). Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities. Pharmacol Ther 196:79–90.
Liu X, Chu K-M (2014). E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int 2014:637308.
Luo G, Zhang Y, Guo P, Wang L, Huang Y, Li K (2017). Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. Int J Cancer 141:1333–1344.
Ma L, Yang R, Gu J, Jiang H, Li H (2020). The expression of AGGF1, FOXC2, and E-cadherin in esophageal carcinoma and their clinical significance. Medicine (Baltim) 99:e22173.
Mendonsa AM, Na T-Y, Gumbiner BM (2018). E-cadherin in contact inhibition and cancer. Oncogene 37:4769–4780.
Na T-Y, Schecterson L, Mendonsa AM, Gumbiner BM (2020). The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci USA 117:5931–5937.
Pohl H, Sirovich B, Welch HG (2010). Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19:1468–1470.
Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P (2017). Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol 12:36–42.
Siewert JR, Stein HJ, Feith M (2006). Adenocarcinoma of the esophago-gastric junction. Scand J Surg 95:260–269.
Sun L, Chen F, Shi W, Qi L, Zhao Z, Zhang J (2014). Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol 9:125.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016). Gastric cancer. Lancet 388:2654–2664.
West JJ, Harris TJC (2016). Cadherin trafficking for tissue morphogenesis: control and consequences. Traffic 17:1233–1243.
Wijnhoven BPL, Tucker ET, Dinjens WNM, Tilanus HW, Pignatelli M (2004). Biochemical analysis and subcellular distribution of E-cadherin-catenin in adenocarcinomas of the gastro-oesophageal junction. Anticancer Res 24:1369–1375.
Wong SHM, Fang CM, Chuah L-H, Leong CO, Ngai SC (2018). E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol 121:11–22.
Xiang Z-L, Zeng Z-C, Fan J, Tang Z-Y, Zeng H-Y, Gao D-M (2011). Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 17:5463–5472.
Xing X, Tang Y-B, Yuan G, Wang Y, Wang J, Yang Y, et al. (2013). The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer 132:2589–2596.
Xu XL, Ling ZQ, Chen SZ, Li B, Ji WH, Mao WM (2014). The impact of E-cadherin expression on the prognosis of esophageal cancer: a meta-analysis. Dis Esophagus 27:79–86.
Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. (2018). Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 6:e555–e567.